Botulinum toxin useful therapeutic option to improve cutaneous flushing, finds study

This study was published in the journal of Dermatologic Surgery by Vincent and colleagues. A systematic review of databases including Medline, Embase, Cochrane CENTRAL, CINAHL, Scopus, and Web of Science was conducted to identify studies assessing the effect of botulinum toxin on flushing. Prespecified outcome measures included clinical flushing score, dermatology life quality index (DLQI), and erythema index (EI).

Meta-analysis was performed to calculate mean differences in these outcomes before and after botulinum toxin treatment at 1-month follow-up.

• Nine studies involving 132 patients were included in the analysis, comprising 2 randomized controlled trials and 7 nonrandomized studies.

• All studies demonstrated a low risk of bias, indicating high quality.

• The meta-analysis revealed a significant decrease in clinical flushing scores by 1.25 points overall (95% confidence interval [CI]: −2.47; −0.04) 1 month after botulinum toxin treatment.

• Mean DLQI scores improved by 9.02 points (95% CI: −19.81; 1.77) following botulinum toxin injections.

• Although the EI (measured by Mexameter) showed improvement in 2 studies, statistical analysis was inconclusive due to insufficient data.

This meta-analysis provides evidence that botulinum toxin effectively reduces clinical flushing scores 1 month after treatment. This finding underscores the potential of botulinum toxin as a therapeutic option for managing cutaneous flushing, offering hope for individuals with this challenging dermatologic condition.

Reference:

Vincent, N., Ravipati, A., Reynolds, J. M., & Kaufman, J. (2024). Efficacy of botulinum toxin in the treatment of cutaneous flushing: A systematic review and meta-analysis. Dermatologic Surgery, 10.1097/DSS.0000000000004073. https://doi.org/10.1097/dss.0000000000004073